Gola A, Kuliczkowski K
Department of Haematology, Medical School, Wrocław, Poland.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1990;117(1):167-72.
Plasma cells derived from marrow aspirates of 21 untreated myeloma patients have been cultured in RPMI 1640 medium containing 3H-thymidine and melphalan. Thereafter plasma cell-labelling index was determined autoradiographically. In 20 patients melphalan caused a measurable decrease in the percentage of labelled plasma cells. Decreases in labelling index ranging from -4% to 3% have been considered as indicating the resistance of myeloma cells to melphalan in vitro. Decreases within this range have been found in 7 patients. In other 13 myelomas with chemosensitive marrow plasma cells, melphalan did reduce the labelling index to values ranging from 4% to 24%. Some clinical implications of the tests are discussed.
从21例未经治疗的骨髓瘤患者的骨髓穿刺物中获取的浆细胞,在含有3H-胸腺嘧啶核苷和美法仑的RPMI 1640培养基中培养。此后,通过放射自显影法测定浆细胞标记指数。在20例患者中,美法仑使标记浆细胞的百分比出现了可测量的下降。标记指数下降范围在-4%至-3%之间被认为表明骨髓瘤细胞在体外对美法仑具有抗性。在7例患者中发现了在此范围内的下降情况。在其他13例骨髓浆细胞对化疗敏感的骨髓瘤患者中,美法仑确实将标记指数降低至4%至24%的范围。讨论了这些检测的一些临床意义。